Journal
EMBO MOLECULAR MEDICINE
Volume 9, Issue 10, Pages 1415-1433Publisher
WILEY
DOI: 10.15252/emmm.201607012
Keywords
ATR; CDK6; FOXO3; ovarian cancer; platinum sensitivity
Categories
Funding
- Ministero della Salute [RF-2010-2309704]
- Associazione Italiana Ricerca sul Cancro (AIRC) [IG 12854]
- CRO
Ask authors/readers for more resources
Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines invitro, in xenografts invivo, and in primary tumor cells derived from platinum-treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available